MarketPR
EARNINGSUS industrial production rises 0.7 percent in SeptemberOct 20EARNINGSOaktree Specialty Lending Sets November 17 Date for Q4 and Full-Year 2026 EarningsOct 20MSMorgan Stanley Lifts Amazon Target to $350, Citing AI-Driven AWS GrowthOct 20ASTCAstrotech approves 1st Detect bonus plan tied to sale proceedsOct 20MDTMedtronic completes MiniMed separation via share exchangeOct 20MACROUS Import and Export Prices Rise on Sticky Inflation ConcernsOct 20STLDSteel Dynamics promotes six executives to support long-term growth strategyOct 20MACROSeptember CPI Jump to 3.7% Pressures Stocks Despite Long-Term GainsOct 20REGULATORYDisney acquires Character.AI assets via bankruptcy restructuringOct 20CRYPTOPlex Media Server flaws under active exploitationOct 20EARNINGSUS industrial production rises 0.7 percent in SeptemberOct 20EARNINGSOaktree Specialty Lending Sets November 17 Date for Q4 and Full-Year 2026 EarningsOct 20MSMorgan Stanley Lifts Amazon Target to $350, Citing AI-Driven AWS GrowthOct 20ASTCAstrotech approves 1st Detect bonus plan tied to sale proceedsOct 20MDTMedtronic completes MiniMed separation via share exchangeOct 20MACROUS Import and Export Prices Rise on Sticky Inflation ConcernsOct 20STLDSteel Dynamics promotes six executives to support long-term growth strategyOct 20MACROSeptember CPI Jump to 3.7% Pressures Stocks Despite Long-Term GainsOct 20REGULATORYDisney acquires Character.AI assets via bankruptcy restructuringOct 20CRYPTOPlex Media Server flaws under active exploitationOct 20
NewsMacro

Pomerantz LLP Files Class Action Against GeneDx Holdings Corp. (NASDAQ: WGS), Warns of Upcoming Deadlines

Pomerantz LLP, the New York-based plaintiff securities law firm, has announced the filing of a class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS), the genomic diagnostics company. The firm is alerting investors who recorded losses on WGS holdings and flagging approaching legal deadlines for participation in the case.

By Grant HalloranMacro DeskJuly 3, 20262 min read
Share

Key takeaways

  • Pomerantz LLP has filed a securities class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS), a genomic diagnostics company.
  • The announcement was issued from New York on July 2, 2026, and warns investors that legal deadlines for participation are approaching.
  • Investors with losses in WGS are directed to contact Pomerantz attorney Danielle Peyton at [email protected] or 646-581-9980.
  • The article does not disclose the specific allegations, the damages sought, the class period, or the exact deadline dates.
  • Neither Pomerantz LLP nor GeneDx Holdings Corp. provided additional comment or a public response at the time of publication.

Pomerantz LLP, the New York-based plaintiff securities law firm, has announced the filing of a class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS), the genomic diagnostics company. The firm is alerting investors who recorded losses on WGS holdings and flagging approaching legal deadlines for participation in the case.

The Lawsuit

Pomerantz LLP, which operates under the Pomerantz Law Firm name in investor-facing communications, confirmed the class action was filed against GeneDx Holdings Corp., traded on the Nasdaq exchange under the ticker WGS. The announcement, issued from New York on July 2, 2026, did not disclose the specific allegations underpinning the complaint, the dollar value of damages sought, or the precise deadline dates in the source material available at publication.

Class action securities cases of this type typically consolidate claims from multiple investors who allege they suffered losses tied to the same set of circumstances. The source does not specify the proposed class period or the nature of the alleged harm.

What Affected Investors Should Know

Pomerantz has directed investors with losses in GeneDx Holdings Corp. to contact attorney Danielle Peyton directly. She can be reached by email at [email protected] or by telephone at 646-581-9980. The firm's announcement emphasizes that deadlines are approaching, which in securities class actions typically refer to the lead plaintiff motion deadline set by the court — after which investors may lose certain rights to take a more active role in directing the litigation.

Investors who believe they may qualify for inclusion in the class are advised to act before those deadlines pass. The source does not specify the exact dates.

GeneDx Holdings Corp. at a Glance

GeneDx Holdings Corp. trades on the Nasdaq under the symbol WGS. The company operates in the genomic sequencing and diagnostics space. The source contains no detail on the company's current share price, market capitalization, or any operational developments tied to the litigation.

Pomerantz LLP did not respond to a request for additional comment at the time of publication. GeneDx Holdings Corp. had not issued a public response to the lawsuit announcement based on materials available at the time this article was written.

Related reading

About this story

Filed by the macro desk of MarketPR on July 3, 2026. Source: prnewswire.com. Indicative figures are not investment advice.

←Back to the news index

More from the Newsroom

All stories →
01Macro

Outstanding margin debt hits $1.5 trillion, a record high

Outstanding margin debt has reached $1.5 trillion, marking a new all-time high. This level of leverage represents the fourth time since 1997 that outstanding margin debt has surged by at least 65% over a short period. The previous three…

Grant Halloran2 min read
02Macro

Berkshire stock hits post-Buffett high as Bending Spoons stake gains

Berkshire Hathaway shares closed Friday at their highest level since Warren Buffett announced in May 2025 that he planned to step down as CEO at the end of that year. Class A shares (BRK.A) ended the session at $798,000, while Class B…

Grant Halloran2 min read
03Macro

Vanguard S&P 500 ETF offers 0.03% expense ratio for $1,000 investment

The Vanguard S&P 500 ETF (VOO) charges an expense ratio of 0.03%, a cost that amounts to $0.30 on a $1,000 investment. The fund, which holds approximately $1.7 trillion in assets, provides exposure to the S&P 500 index, a benchmark…

Grant Halloran2 min read

Frequently asked

Who filed the class action against GeneDx Holdings Corp.?

The class action was filed by Pomerantz LLP, a New York-based plaintiff securities law firm that also operates under the Pomerantz Law Firm name.

How can affected WGS investors get involved?

Investors with losses in GeneDx Holdings Corp. can contact attorney Danielle Peyton by email at [email protected] or by phone at 646-581-9980, and are advised to act before the approaching deadlines.

What are the specific allegations in the lawsuit?

The article does not disclose the specific allegations, the dollar value of damages sought, the proposed class period, or the exact deadline dates.

What does the deadline in the announcement refer to?

In securities class actions this deadline typically refers to the court-set lead plaintiff motion deadline, after which investors may lose certain rights to take a more active role in directing the litigation.

What does GeneDx Holdings Corp. do?

GeneDx Holdings Corp. trades on the Nasdaq under the symbol WGS and operates in the genomic sequencing and diagnostics space.